GPP
PRAX icon

Great Point Partners’s Praxis Precision Medicines PRAX Stock Holding History

Great Point Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-135,503
Closed -$1.64M – 49
2023
Q1 		$1.64M Buy
+135,503
New +$5.72M 0.32% 39

Other funds holding PRAX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Great Point Partners's PRAX Position: Q2 2023 in Review

Great Point Partners sold out of Praxis Precision Medicines (PRAX) in Q2 2023, closing a stake of 135,503 shares — an estimated $1.64M sold.

Great Point Partners first reported a position in PRAX in Q1 2023 and held it in 1 quarter. The position peaked at $1.64M in Q1 2023. 78 funds tracked by Wall St. Rank hold PRAX as of Q2 2023.

  • Great Point Partners reported no remaining Praxis Precision Medicines position as of Q2 2023 after selling out during the quarter.
  • Great Point Partners sold 135,503 Praxis Precision Medicines shares in Q2 2023, an estimated $1.64M.
  • Great Point Partners first reported a position in Praxis Precision Medicines in Q1 2023 and held it in 1 quarter.
  • Great Point Partners's Praxis Precision Medicines position peaked at $1.64M in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.